NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

An update of protease inhibitor (PI) use in 233 pregnancies.

Morris AB, Dobles AR, Zorrilla C, Anderson JR, Cu-Uvin S, Keller J, Harwell JI, Garb JL; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. WePeB5917.

Community Research Initiative of New England, Springfield, MA, United States

OBJECTIVES: To better understand the effects of PIs in pregnancy on prematurity, maternal & infant adverse events, and infant outcomes. METHODS: Medical records of pregnant women treated with PIs at 5 sites were reviewed. Demographics, maternal CD4 and viral load (VL) data, prematurity, infant infection status, and maternal and infant adverse events were recorded. RESULTS 233 pregnancies reported. 87% acquired HIV heterosexually. 73% asymptomatic HIV infection. Mean age:28 yr. 47% Latina;31% African-American;15% Caucasian. Mean CD4 cells at beginning of pregnancy 403+/-242mm3; mean VL 59,883 copies/ml [range,<50-3,611,554]. 53% ART naive; 70% PI naive. 215 on nelfinavir, 13 saquinavir, 16 indinavir, 10 ritonavir. 12 >1 PI. 19% on PIs at conception. 18% began PIs in 1st trimester; 42% 2nd; 22% 3rd. 56% had VL <400 copies/ml at latest test in pregnancy. 55% delivered by elective cesarean section (CS); 10% by unscheduled CS. 22.5% [95%CI,17-28%] pregnancies were <37 weeks gestation including 3 twin and 1 triplet pregnancy. 25% [95%CI,19-31%] of infants had birth weights (BW) <2500 grams including 4 sets of twins and 1 set of triplets. Mean BW:2817+/-626 grams. Obstetric complications include 2 placenta previa, 2 abruption, 3 gestational diabetes, 4 oligohydramnios, 5 chorioamnionitis, 8 preeclampsia, 2 spontaneous abortions, 3 fetal demise and 1stillbirth. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9%, [95%CI, 0-2.2%]. 1 HIV+ infant delivered by elective CS at 37.14 wks to mother with VL of 5403; the other delivered by unscheduled CS at 32.86 wks to a mother with undetectable VL but multiple STDs during pregnancy. CONCLUSIONS: In this series perinatal transmission is low. The prematurity rate is similar to prior data in HIV+ women not on PIs. Adverse events in mothers on PIs are similar to our prior report in the same population and to that of the general population.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Anti-HIV Agents
  • Birth Weight
  • CD4-Positive T-Lymphocytes
  • Cesarean Section
  • Female
  • HIV
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Infant
  • Pregnancy
  • Pregnancy Complications
  • Pregnancy Outcome
  • Pregnancy, Multiple
  • Protease Inhibitors
  • Triplets
  • Twins
  • Viral Load
  • surgery
  • utilization
Other ID:
  • GWAIDS0014398
UI: 102251896

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov